Due to the difficulty in synthesizing glycan standards, as well as their high cost and limited availability, current quantitative glycan analysis by LC-MS and MALDI-MS primarily relies on relative quantification using isotope labeling. Stable isotope labeling is a technique that uses non-radioactive isotopes to label biomolecules. It enables the labeling of glycans in organisms under different physiological or pathological states. The samples are then mixed in equal proportions and analyzed by mass spectrometry. Because isotopes share identical chemical properties but have different masses, they exhibit the same ionization efficiency in the mass spectrometer and appear as a pair of characteristic isotopic peaks in the spectrum. By comparing the relative abundance of this peak pair, changes in glycan expression levels across different conditions can be accurately analyzed.

Addressing this critical need, Professor Junzhe Min from Yanbian University has developed two novel isotopic mass spectrometry probes: d0-BOTC and d5-BOTC. These probes offer a dual advantage: they significantly enhance the detection sensitivity of glycans in mass spectrometry, and when used in combination, they enable relative quantification of glycans without the need for expensive standards. The d0/d5-BOTC probes provide a new class of high-sensitivity isotopic derivatization reagents, facilitating advanced research in differential glycomics and the screening of novel disease-related glycan biomarkers.

Key Advantages of d0-BOTC and d5-BOTC Probes

• High Purity: 96% purity ensures reliable and reproducible results.
• Excellent Selectivity: The combined use of d0-BOTC and d5-BOTC successfully identified 13 free oligosaccharide derivatives in Cetuximab. This included 7 complex-type glycans, 4 hybrid-type glycans, and 2 high-mannose-type glycans (Figure 1), demonstrating the probes' high selectivity.
• High Sensitivity for Biomarker Discovery: Leveraging the high sensitivity of d0/d5-BOTC, researchers successfully screened and identified 14 distinct glycan biomarkers in serum samples from patients with acute myocardial infarction (AMI) (Figure 2)

Related Product:

• #Cat:9426279  3-Benzoyl-2-oxothiazolidine-4-carboxylic acid (d0-BOTC), 96%
• #Cat:9426280  3-(2,3,4,5,6-Pentadeuterio-benzoyl)-2-oxothiazolidine-4-carboxylate acid (d5-botc), 96%

Notice for Bulk/Industrial Orders

To ensure you receive the most accurate pricing and terms for your specific needs, all purchases require a custom quote.

Please contact our sales team to discuss your requirements and receive a formal quotation.

We appreciate your interest and look forward to supporting your large-scale projects.

Contact Us

Professor Min Junzhe, Ph.D. in Pharmaceutical Sciences, Professor and Discipline Leader at Yanbian University, is recognized as a Jilin Province "Top 100 High-level Innovation and Entrepreneurship Talent", "Tumen River Scholar", and "Western Light" Visiting Scholar. He serves as Visiting Professor at the University of Shizuoka, Japan, and Associate Editor of Frontiers in Chemistry. His research focuses on high-sensitivity MS probes for chiral metabolomics and glycomics, mechanistic studies of traditional medicines, and non-invasive diagnostic kits for chronic diseases. He has directed three MEXT Japan projects and three additional Japan-funded programs, led/completed four NSFC projects and four provincial/ministerial projects, authored 130+ SCI papers, and holds six invention patents (three Japan, three China). He has mentored over ten outstanding Ph.D. graduates, including "Young Tumen River Scholar" recipients.